In this podcast interview with Dr. Fred Grossman, President and Chief Medical Officer of Coya, the following key points were discussed:

– The podcast, “The Patients Speak,” aims to bridge the gap between healthcare science and the patient perspective.

– Dr. Grossman highlighted the significant unmet needs in conditions like ALS and Alzheimer’s disease, emphasizing the personal impact on patients and their families.

– ALS (Lou Gehrig’s disease) is a rapidly progressive neurodegenerative disease that affects muscle function, speech, and respiration, with a high fatality rate.

– Alzheimer’s disease is also a devastating condition, and patients and their families are eagerly seeking treatments.

– The discussion touched on the importance of considering patients’ perspectives on daily activities, which are greatly affected by these conditions.

– Dr. Grossman emphasized the need for objective measures in clinical trials while acknowledging the importance of subjective input from patients and their families.

– Patients’ altruism and desire to contribute to research were highlighted as essential drivers in clinical trials.

– Dr. Grossman discussed Coya’s focus on regulatory T cells (Tregs) as a key cellular target in treating ALS due to their role in regulating inflammation.

– Coya’s treatment, Coya 302, aims to increase the number and function of Tregs to stabilize the immune system and halt ALS progression.

– The potential impact of Coya 302 was discussed, with the aim of prolonging survival and improving patients’ quality of life.

– Dr. Grossman mentioned that Coya is planning a large-scale study for Koya 302 with a potential start in six months.

– Collaboration with patient advocacy groups and the Healy Platform Trial was highlighted as a way to involve patients in research and speed up progress.

– The importance of clear and honest communication between patients and healthcare providers was emphasized, with patients having the right to know what to expect in their condition.

Fred’s Website

BSB Media